Ginkgo Biloba: Circulation, Memory and Cognitive Support
Ginkgo is among the most-studied botanicals in existence, and the largest prevention trial was decisively negative. Where the remaining evidence actually points.
The Short Answer
Ginkgo biloba leaf extract, standardised as EGb 761 to twenty-four percent flavone glycosides and six percent terpene lactones, is one of the most extensively trialled botanicals in the world. The largest and best-conducted trial, following over three thousand older adults for a median of six years, found no reduction in dementia incidence or cognitive decline. Where evidence persists is in existing cognitive impairment, where meta-analyses report modest benefits at 240 milligrams per day, and in specific indications including tinnitus and peripheral arterial claudication. It has a real bleeding interaction that matters more than most botanical cautions.
What Ginkgo Contains and Does
Standardised ginkgo extract contains two active fractions. Flavone glycosides, principally quercetin, kaempferol and isorhamnetin derivatives, contribute antioxidant and vascular effects. Terpene lactones, the ginkgolides and bilobalide, are structurally unusual compounds largely unique to this plant, and ginkgolide B is a potent platelet-activating factor antagonist, which is both a mechanism and the source of the bleeding concern.
Documented activities include increased cerebral blood flow, reduced blood viscosity, platelet-activating factor antagonism, antioxidant effects, and mitochondrial protection in animal models. Bilobalide has effects on GABAergic signalling and on mitochondrial respiration.
Standardised extract also has ginkgolic acids removed to below five parts per million, because these are allergenic and cytotoxic. Crude leaf preparations and teas do not have this processing and are not equivalent.
The Negative Prevention Trial
The most important single piece of evidence about ginkgo is a null result, and it deserves prominence rather than a footnote.
A large randomised trial enrolled over three thousand adults aged seventy-five and older, with normal cognition or mild cognitive impairment, and gave 120 milligrams of EGb 761 twice daily or placebo for a median of six years. It found no reduction in the incidence of all-cause dementia or Alzheimer's dementia, and a companion analysis found no reduction in the rate of cognitive decline.
This is the kind of trial the field needs more of: large, long, well conducted, with a hard endpoint, testing a widely used intervention. Its result should be the anchor for any discussion of ginkgo for prevention, and it means the common framing of ginkgo as protective against cognitive decline is not supported.
A separate large European trial in older adults with memory complaints similarly found no effect on progression to dementia.
Where Evidence Persists
Existing cognitive impairment and dementia
Meta-analyses and a Cochrane review of ginkgo in cognitive impairment and dementia report modest benefits on cognition and activities of daily living at 240 milligrams per day, with the evidence described as inconsistent and the effects small. European clinical guidance in some countries includes ginkgo as an option in mild cognitive impairment, which reflects a different regulatory tradition rather than stronger evidence.
Tinnitus
Trials of EGb 761 in tinnitus, particularly where associated with cognitive impairment, report modest reductions in symptom severity. The broader tinnitus literature is mixed.
Peripheral arterial claudication
Meta-analyses report small increases in pain-free walking distance, of questionable clinical importance relative to exercise therapy.
Vertigo and dizziness
Trials report improvements, with the same standardised extract, in vestibular contexts.
Acute cognition in healthy adults
Small trials report acute effects on memory and attention measures in healthy young adults, inconsistently, and the effect sizes are small. This is not a reliable finding.
The Bleeding Question
Ginkgolide B is a platelet-activating factor antagonist, so an antiplatelet effect is mechanistic rather than speculative.
Case reports describe spontaneous bleeding events including intracranial haemorrhage in ginkgo users, several involving concurrent antiplatelet or anticoagulant medication. Systematic reviews of randomised trials, by contrast, have not found a statistically significant increase in bleeding events, which suggests the absolute frequency is low.
The reasonable reading: a real pharmacological effect with an uncertain but low event rate, which becomes clinically important in combination. Practical implications are specific. Anyone on warfarin, direct oral anticoagulants, aspirin or clopidogrel should not add ginkgo without clinical involvement. It should be stopped at least two weeks before elective surgery. And anyone with a bleeding disorder or a history of haemorrhagic stroke should avoid it.
Ginkgo also inhibits and induces several cytochrome P450 enzymes, with reported effects on the metabolism of some anticonvulsants, and there are reports of reduced efficacy of certain seizure medications, which is a serious interaction in that population.
Dose, Product Selection and Practical Position
- 120 to 240 mg per day of standardised extract in divided doses. Cognitive trials generally used 240 mg; the prevention trial used 240 mg.
- Standardisation. Twenty-four percent flavone glycosides, six percent terpene lactones, ginkgolic acids below five parts per million. Products not stating this cannot be matched to the trial material.
- Duration. Trials in cognitive impairment ran twenty-two to twenty-six weeks. Acute effects, where reported, are small.
Ginkgo is a genuine test of how a person weighs evidence. It has a vast literature, a strong traditional and commercial position, a decisively negative large prevention trial, modest effects in existing impairment, and a real interaction profile.
The defensible position: not for prevention in cognitively healthy adults, since the best trial answered that question. Possibly worth discussing with a clinician in existing mild cognitive impairment, where guidance in some jurisdictions includes it. Reasonable to consider for tinnitus or vestibular symptoms with modest expectations. And off the table for anyone on antiplatelet or anticoagulant therapy, approaching surgery, or on seizure medication, without clinical direction.
The AEONNN Perspective
Ginkgo is the article where the Meta-Consensus layer matters most, because the popular understanding of this compound and the best available trial point in opposite directions. A large, long, well-conducted prevention trial returned a null result, and a platform that averaged that against decades of smaller positive studies would misinform a member about the specific question they are most likely to be asking.
It maps to Cognition and Neuroprotection and to Metabolic and Cardiovascular Health through the vascular effects. Its Evidence Level differs by indication: weak for prevention in healthy adults, Level B in existing impairment, and that distinction is exactly what a single score would erase.
The Safety layer holds the antiplatelet and anticonvulsant interactions as gating. For a member on anticoagulant therapy or seizure medication, the correct output is not a lower dose but no recommendation without clinical involvement, and the perioperative window is a Contingency case with a concrete two-week instruction.
Pillar Matrix mapping
Cognition and Neuroprotection, Metabolic and Cardiovascular Health
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Safety Layer (DrugBank, FAERS)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Regulatory Layer (EFSA, FDA, EMA)
Frequently Asked
Does ginkgo prevent dementia?
No. A randomised trial of over three thousand older adults followed for a median of six years found no reduction in dementia incidence or in the rate of cognitive decline at 240 mg per day.
Is ginkgo useful for anything cognitive?
Meta-analyses in existing cognitive impairment and dementia report modest, inconsistent benefits on cognition and daily function at 240 mg per day. Some European guidance includes it as an option in mild cognitive impairment.
How much ginkgo should be taken?
120 to 240 mg per day of extract standardised to twenty-four percent flavone glycosides and six percent terpene lactones, in divided doses. Cognitive trials generally used 240 mg.
Does ginkgo increase bleeding risk?
Ginkgolide B is a platelet-activating factor antagonist, so the antiplatelet effect is real. Case reports describe serious bleeding events, while randomised trial meta-analyses have not found a significant increase, suggesting a low event rate that matters most in combination with antiplatelet or anticoagulant therapy.
Who should avoid ginkgo?
Anyone on anticoagulant or antiplatelet therapy without clinical involvement, anyone within two weeks of elective surgery, anyone with a bleeding disorder or history of haemorrhagic stroke, and anyone on seizure medication given reports of reduced efficacy.
Is ginkgo tea equivalent to the extract?
No. Standardised extract has ginkgolic acids removed to below five parts per million because they are allergenic and cytotoxic. Crude leaf preparations do not undergo that processing.
Does ginkgo help tinnitus?
Trials of the standardised extract report modest reductions in symptom severity, particularly where tinnitus accompanies cognitive impairment. The wider tinnitus literature is mixed.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.